Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Rectal Neoplasms 1Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

venetoclax 30obinutuzumab 22acalabrutinib 20Specimen Handling 19ibrutinib 16Cyclophosphamide 15Biopsy 15pirtobrutinib 14zanubrutinib 12fludarabine 12Rituximab 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 5Stem Cell Transplantation 4Blood Component Removal 4ARQ531 4idelalisib 3fludarabine phosphate 3Whole-Body Irradiation 3Mycophenolic Acid 3tocilizumab 2polatuzumab vedotin 2Watchful Waiting 2Sirolimus 2Prednisone 2Pneumococcal Vaccines 2Lisaftoclax 2Leukapheresis 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × Endoscopy, Gastrointestinal × Clear all
NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡